Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Allergic Rhinitis
- Cough
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A Randomized, Double-blind, Placebo Controlled StudyMasking: Triple (Participant, Investigator, Outcomes Assessor)Masking Description: Allocation of medication is conducted by an independent physician who is not a co-investigator of the study.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
This is a randomized, double blind, placebo controlled trial in which a total of 78 participants who have cough (? 3 weeks) and symptoms of allergic rhinitis will be enrolled. Study participants will be randomly assigned to either active treatment or placebo group. The subjects in active treatment g...
This is a randomized, double blind, placebo controlled trial in which a total of 78 participants who have cough (? 3 weeks) and symptoms of allergic rhinitis will be enrolled. Study participants will be randomly assigned to either active treatment or placebo group. The subjects in active treatment groups will be treated with daily oral bepotastine for 2 weeks, while those in placebo group will take identical-looking tablets. The efficacy of bepotastine will be assessed at the end of 2-week intervention using leicester cough questionnaire.
Tracking Information
- NCT #
- NCT04877678
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Woo-Jung Song Asan Medical Center
Get Well Soon